What Mounjaro Costs Without Insurance
Without insurance, Mounjaro is typically high-cost at retail pharmacies—comparable to other GLP-1 receptor agonists in the same class. This is the cash price before any discounts or coverage are applied.
Very few patients pay this amount. Between insurance coverage, Eli Lilly’s savings programs, and other financial assistance, most patients significantly reduce their out-of-pocket cost.
Diabetes vs. weight loss coverage: Mounjaro is FDA-approved for type 2 diabetes and is well-covered by most insurance plans for that indication. For weight management, the FDA-approved product is Zepbound—same molecule, different coverage pathway. At PEAK, we prescribe Zepbound for weight loss.
Insurance Coverage for Mounjaro
For Type 2 Diabetes
Most commercial and government insurance plans cover Mounjaro for type 2 diabetes, though typically with prior authorization:
- Commercial plans: Generally covered as a Tier 3 or specialty medication. Copays vary by formulary tier and plan design.
- Medicare Part D: Coverage varies by plan. Many Medicare plans have added Mounjaro to their formularies as clinical evidence has grown
- Medicaid: Coverage varies by state. Most state Medicaid programs cover GLP-1 medications for diabetes with prior authorization
- TRICARE: Covers Mounjaro for type 2 diabetes with appropriate documentation
For Weight Management (as Zepbound)
Insurance coverage for tirzepatide as a weight loss medication has expanded significantly but remains inconsistent:
- Growing number of commercial plans cover Zepbound for weight management
- Medicare Part D generally does not cover weight loss medications (legislative change is being pursued)
- Some employer-sponsored plans include anti-obesity medication benefits
Eli Lilly Savings Programs
Eli Lilly offers several programs to reduce Mounjaro costs for eligible patients:
Mounjaro Savings Card (Commercially Insured)
- Eligible patients may have substantially reduced out-of-pocket cost
- Available for commercially insured patients only
- Not available for government insurance (Medicare, Medicaid, TRICARE)
- Maximum savings amount per fill applies (check current terms)
Note: PEAK accepts Anthem, Cigna, Aetna, UnitedHealthcare, Sentara, and TRICARE commercial plans. We do not accept Medicare or Medicaid.
Lilly Direct
Eli Lilly has introduced Lilly Direct—a program that may offer cash-pay pricing for patients without adequate insurance coverage. Availability and pricing may vary.
| Situation | Typical Cost | Best Strategy |
|---|---|---|
| Commercial insurance + savings card | Often lowest out-of-pocket | Use Lilly savings card at pharmacy |
| Commercial insurance, no savings card | Varies by plan copay | Activate savings card immediately |
| No insurance coverage | Typically high retail cost | Patient assistance + Lilly Direct |
| Medicare Part D | Varies by plan | Check formulary; patient assistance if needed |
Patient Assistance Programs
- Lilly Cares Patient Assistance Program: Provides free medication to eligible patients below specific income thresholds. Requires application and income documentation
- NeedyMeds: Database of financial assistance programs searchable by medication
- RxAssist: Full directory of patient assistance programs
- Pharmacy discount programs: GoodRx and similar services may offer reduced cash prices at certain pharmacies
Mounjaro vs. Zepbound: Cost Comparison
Both contain identical tirzepatide at the same doses. The cost difference comes from insurance coverage pathways:
| Factor | Mounjaro (Diabetes) | Zepbound (Weight Loss) |
|---|---|---|
| List price | High without insurance | High without insurance |
| Insurance for diabetes | Widely covered with PA | Not approved for diabetes |
| Insurance for weight loss | Off-label; often denied | FDA-approved; growing coverage |
| Savings card | Lilly savings program | Separate Zepbound savings program |
If your primary goal is weight management, using Zepbound with its FDA indication for obesity typically provides a clearer insurance pathway than using Mounjaro off-label for weight loss.
Maximizing Your Coverage
- Prior authorization: Work with your provider to submit thorough PA documentation. Approval rates are high when medical necessity is clearly documented
- Appeal denials: Initial denials are often overturned. Your provider can submit additional documentation or request peer-to-peer review
- Check formulary tier: Some plans place Mounjaro on different tiers with different copays. Formulary exceptions may move it to a lower tier
- Specialty pharmacy: Some insurers route GLP-1 medications through specialty pharmacies with different (sometimes lower) copay structures
- Combine strategies: Insurance coverage + savings card + specialty pharmacy can minimize costs to the lowest possible amount
Boxed warning — thyroid C-cell tumors: Tirzepatide (Mounjaro/Zepbound) carries an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
